RecruitingNCT07748169

An Observational Study of Patients With Dermatologic Disease

Sponsor

Target PharmaSolutions, Inc.

Enrollment

2,000,000 participants

Start Date

Aug 1, 2026

Study Type

OBSERVATIONAL

Conditions

Alopecia Areata Atopic Dermatitis Vitiligo Hidradenitis Suppurativa (HS)

Summary

TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients. The study includes patients managed for DD of any etiology in usual clinical practice in the United States and addresses important clinical questions regarding the management of DD by collecting and analyzing data from patients at academic medical centers and community medical practices and/or data from providers who treat them.

Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with alopecia areata, atopic dermatitis, and other related conditions. The study is currently recruiting participants at 3 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(3)

Wake Forest University Health Science

Winston-Salem, North Carolina, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Medical University of South Carolina

Charleston, South Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07748169

Related Trials

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

NCT072629831 location

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

NCT06873945114 locations